BMS Buys iPierian and its Anti-Tau Programme for a Potential US$725 M
By Heather Cartwright
Pharma Deals Review: Vol 2014 Issue 5 (Table of Contents)
Published: 28 May-2014
DOI: 10.3833/pdr.v2014.i5.2031 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Seven months after separating into two companies, neurodegenerative disease specialist iPierian has agreed to be acquired by Bristol-Myers Squibb (BMS) for US$175 M in cash upfront plus potential milestone payments of up to US$550 M and royalties...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS